Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jul 2:3:120.
doi: 10.3389/fgene.2012.00120. eCollection 2012.

miR-34 - a microRNA replacement therapy is headed to the clinic

Andreas G Bader  1
Affiliations

miR-34 - a microRNA replacement therapy is headed to the clinic

Andreas G Bader. Front Genet. .

Abstract

MicroRNA-34 (miR-34) is a master regulator of tumor suppression. It is downregulated in numerous cancers and inhibits malignant growth by repressing genes involved in various oncogenic signaling pathways. Consequently, miR-34 antagonizes processes that are necessary for basic cancer cell viability as well as cancer stemness, metastasis, and chemoresistance. This broad anti-oncogenic activity holds the prospect of creating a new remedy that is effective against tumor heterogeneity. This review focuses on the molecular mechanisms of miR-34-mediated tumor suppression, pharmacologies in animal models of cancer, and a status update of a miR-34 therapy that may be among the first miRNA mimics to reach the clinic.

Keywords: miR-34; miR-34a; miRNA; miRNA replacement; miRNA therapeutics.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Cancer processes counteracted by miR-34.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Akao Y., Noguchi S., Iio A., Kojima K., Takagi T., Naoe T. (2010). Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer Lett. 300 197–204 - PubMed
    1. Asslaber D., Pinon J. D., Seyfried I., Desch P., Stocher M., Tinhofer I., Egle A., Merkel O., Greil R. (2010). microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia. Blood 115 4191–4197 - PubMed
    1. Bader A. G., Brown D., Winkler M. (2010). The promise of microRNA replacement therapy. Cancer Res. 70 7027–7030 - PMC - PubMed
    1. Bader A. G., Daige C. L., Kelnar K., Priddy L., Dysart S., Wiggins J., Zhao J., Leatherbury N., Omotola M., Stoudemire J., Lammers P., Brown D. (2012). Preclinical data of a microRNA-based therapy for hepatocellular carcinoma. Annual AACR Conference Presentation, March 31–April 4, 2012, Chicago, IL
    1. Bommer G. T., Gerin I., Feng Y., Kaczorowski A. J., Kuick R., Love R. E., Zhai Y., Giordano T. J., Qin Z. S., Moore B. B., MacDougald O. A., Cho K. R., Fearon E. R. (2007). p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr. Biol. 17 1298–1307 - PubMed

LinkOut - more resources